Payment overview · 2025
General Payments
$229.59
13 reported records · 8 companies
Healthcare provider profile · identity verified
Kevin L Pounds, MD
Allopathic & Osteopathic Physicians|Family Medicine · TUCSON, AZ · NPI 1831138569
Verified facts
What the public records show
CMS Open Payments records show Kevin L Pounds, MD received $229.59 in general payments during 2025 across 13 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.24 | 26.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.95 | 22.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.53 | 15.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.83 | 8.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.56 | 7.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.93 | 7.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.03 | 6.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.52 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $189.75 | 11 |
| Education | $39.84 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.24 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.95 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 89 |
| Lisinopril | Lisinopril | 247 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 70 |
| Simvastatin | Simvastatin | 185 | 62 |
| Losartan Potassium | Losartan Potassium | 167 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 50 |
| Omeprazole | Omeprazole | 129 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 39 |
| Metformin Hcl | Metformin Hcl | 117 | 35 |
| Allopurinol | Allopurinol | 115 | 35 |
| Gabapentin | Gabapentin | 109 | 32 |
| Metformin Hcl Er | Metformin Hcl | 98 | 31 |
| Montelukast Sodium | Montelukast Sodium | 93 | 30 |
| Alendronate Sodium | Alendronate Sodium | 84 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 19 |
| Trazodone Hcl | Trazodone Hcl | 69 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 15 |
| Finasteride | Finasteride | 62 | 19 |
| Lovastatin | Lovastatin | 55 | 17 |
| Carvedilol | Carvedilol | 50 | 19 |
| Furosemide | Furosemide | 50 | 21 |
| Tramadol Hcl | Tramadol Hcl | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 15 |
| Lorazepam | Lorazepam | 41 | 17 |
| Pregabalin | Pregabalin | 41 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Famotidine | Famotidine | 38 | 15 |
| Sertraline Hcl | Sertraline Hcl | 38 | 14 |
| Celecoxib | Celecoxib | 37 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 12 |
| Spironolactone | Spironolactone | 35 | 11 |
| Potassium Chloride | Potassium Chloride | 34 | 15 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 11 |
| Prednisone | Prednisone | 29 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 11 |
| Meloxicam | Meloxicam | 27 | 12 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.59 · 13 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, FREESTYLE LIBRE 3, INSPIRE, Kerendia, OTEZLA, REPATHA, SHINGRIX, VRAYLAR, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error